{
    "clinical_study": {
        "@rank": "20036", 
        "arm_group": [
            {
                "arm_group_label": "Buparid; Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "Buparid 1 mg budesonide/2 ml nebuliser solution"
            }, 
            {
                "arm_group_label": "Budes; Treatment B", 
                "arm_group_type": "Active Comparator", 
                "description": "Budes\u00ae Nasal Spray 50 \u00b5g budesonide/pump"
            }
        ], 
        "brief_summary": {
            "textblock": "The study should create data for the selection of a clinically relevant primary endpoint to\n      assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the\n      therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the\n      selected parameter should allow a correlation between an objective methodology and the\n      clinical outcome of the study patients."
        }, 
        "brief_title": "Buparid/PARI SINUS Versus Budes\u00ae Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Rhinosinusitis", 
            "Chronic Polyposis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Nasopharyngeal Neoplasms", 
                "Sinusitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with confirmed diagnosis of chronic rhinosinusitis (CRS) with polyposis nasi\n             grade I-II\n\n          -  Patient with a PNIF of > 7 l/min separated for left and right side of the nose\n\n          -  Patient's written informed consent\n\n          -  Male or female,>= 18 years of age\n\n          -  Patient is able to undergo nasal therapy without restrictions\n\n          -  Capable of understanding the purpose and risk of the clinical trial\n\n          -  Female patients with childbearing potential must have a negative urine pregnancy test\n             prior to first IMP administration\n\n          -  Patient has completed correctly the diary during the Wash-in Phase\n\n        Exclusion Criteria:\n\n          -  Patients with cystic fibrosis\n\n          -  Patients with polyposis nasi grade III-IV\n\n          -  Patients with prior sinonasal surgery (exemption: polypectomy)\n\n          -  Patients with primary ciliaritis\n\n          -  Patients with asthma\n\n          -  Patients with active and symptomatic allergies against aeroallergens\n\n          -  Pregnant or breastfeeding women\n\n          -  Patients with suspected active upper airway infection\n\n          -  Receipt of an investigational drug as part of a clinical trial within 4 weeks prior\n             to first administration of IMP\n\n          -  Drug or alcohol abuse\n\n          -  End-stage malignancies\n\n          -  Known hypersensitivity to Budesonide\n\n          -  Patients with oral steroid therapy within the last 4 weeks\n\n          -  Patients with frequent epistaxis (> 2 per month)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946711", 
            "org_study_id": "12082.101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Buparid; Treatment A", 
                "description": "Inhalation", 
                "intervention_name": "Budesonide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Budes; Treatment B", 
                "description": "Nasal spray", 
                "intervention_name": "Budesonide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Budesonide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CRS", 
            "polyposis"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": [
            {
                "contact": {
                    "email": "martin.canis@med.uni-goettingen.de", 
                    "last_name": "Martin Canis, Prof", 
                    "phone": "+49 551 3989", 
                    "phone_ext": "71"
                }, 
                "facility": {
                    "address": {
                        "city": "Goettingen", 
                        "country": "Germany", 
                        "zip": "37075"
                    }, 
                    "name": "University Goettingen"
                }, 
                "investigator": {
                    "last_name": "Martin Canis, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sven.becker@med.uni-muenchen.de", 
                    "last_name": "Sven Becker, MD", 
                    "phone": "+49 89 7095", 
                    "phone_ext": "0"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "81377"
                    }, 
                    "name": "University LMU Munich"
                }, 
                "investigator": {
                    "last_name": "Sven Becker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study to Investigate the Efficacy and Safety of Buparid/PARI SINUS Versus Budes\u00ae Nasal Spray in the Therapy of Chronic Rhinosinusitis (CRS) With Polyposis Nasi in Adult Patients", 
        "other_outcome": [
            {
                "description": "SNOT 22 (Sino-Nasal Outcome Test 22)", 
                "measure": "Health-specific quality of life", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Rhinonanometry", 
                "measure": "Nasal obstruction", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Endoscopy (classification according to Rasp et al. 2000)", 
                "measure": "Expansion of polyposis nasi", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 8"
            }
        ], 
        "overall_contact": {
            "email": "s.prante@pari.de", 
            "last_name": "Stefanie Prante", 
            "phone": "+49 89 742846", 
            "phone_ext": "830"
        }, 
        "overall_contact_backup": {
            "email": "g.boerner@pari.de", 
            "last_name": "Gerhard Boerner", 
            "phone": "+49 89 742846", 
            "phone_ext": "59"
        }, 
        "overall_official": {
            "affiliation": "Ludwig-Maximilians - University of Munich", 
            "last_name": "Sven Becker, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Magnetic Resonance Imaging\nThickness of mucosa\nLund-Mackay-Score", 
            "measure": "Change of inflammation of the nasal mucosa and paranasal sinus", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline at Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946711"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Treatment-emergent adverse events (AEs)", 
            "measure": "Safety assessment", 
            "safety_issue": "Yes", 
            "time_frame": "26 weeks"
        }, 
        "source": "Pari Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pari Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}